GLP-1 receptor agonists typically produce greater HbA1c reductions, promote weight loss, and have proven cardiovascular benefits, whereas sitagliptin is weight-neutral with lower hypoglycaemia risk
Cell immune deconvolution results shown in Supplementary Fig
As personalized care becomes a central focus in healthcare, these medications provide new hope for individuals battling obesity and type 2 diabetes
"FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014"
For patients, it is smart to keep taking thyroid medication consistently, on schedule, and to report any new symptoms after starting GLP-1/GIP therapy
Pancreatitis : Although rare, there is a risk of developing pancreatitis, which is inflammation of the pancreas